Expression of WTH3 in breast cancer tissue and the effects on the biological behavior of breast cancer cells

Gan, Lin; Zuo, Guo‐Wei; Wang, Ting; Min, Jie; Wang, Yadong; Wang, Yongyue; Liu, Gang

doi:10.3892/etm.2015.2458

Cited by 4 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as an interesting prognostic factor was supported by the literature, which brought us to perform further experiments on the protein RAB6C [69,70,104,105,[127][128][129][130].…”

Section: Snp Selection Among Whole Genome Gene Copy Datamentioning

confidence: 76%

“…By a statistic approach and support from the literature, which suggests interesting properties of RAB6C, this gene was selected and the protein expression was further analyzed in an independent cohort [69,70,104,105,[127][128][129][130]. The prognostic value of RAB6C was significant both at gene copy level and protein expression level.…”

Section: Paper IIImentioning

confidence: 99%

“…RAB6C which was studied in paper III and IV in this thesis has been suggested as a tumor suppressor and is regulated by p53 [69,70].…”

Section: Oncogenesmentioning

confidence: 99%

“…As the RAB6C gene is directly regulated by the protein p53 it is suggested to promote apoptosis [105]. RAB6C has also been shown to be able to inhibit the proliferation of breast cancer cells and decrease their invasion ability [70].…”

Section: Rab6cmentioning

confidence: 99%

“…Rab-GTPases are members of the RAS family and their expression product can bind to GTP [69,70,103]. They are involved in regulating intracellular protein trafficking pathways and hypothesized to have altered expression levels in certain cancer [69] .…”

Section: Rab6cmentioning

confidence: 99%

See 4 more Smart Citations

Long-term prognostic and predictive factors in hormone receptor positive breast cancer

Fohlin¹

View full text Add to dashboard Cite

“…as an interesting prognostic factor was supported by the literature, which brought us to perform further experiments on the protein RAB6C [69,70,104,105,[127][128][129][130].…”

Section: Snp Selection Among Whole Genome Gene Copy Datamentioning

confidence: 76%

Section: Paper IIImentioning

confidence: 99%

“…RAB6C which was studied in paper III and IV in this thesis has been suggested as a tumor suppressor and is regulated by p53 [69,70].…”

Section: Oncogenesmentioning

confidence: 99%

Section: Rab6cmentioning

confidence: 99%

Section: Rab6cmentioning

confidence: 99%

See 3 more Smart Citations

Long-term prognostic and predictive factors in hormone receptor positive breast cancer

Fohlin¹

View full text Add to dashboard Cite

Salivary DNA methylation markers for cancer of oral cavity

Kabekkodu

Chakrabarty

Varghese

et al. 2022

CBM

View full text Add to dashboard Cite

PURPOSE: Aberrant DNA methylation plays a crucial role in oral carcinogenesis. Our previous study demonstrated hypermethylation of DAPK1, LRPPRC, RAB6C, and ZNF471 promoters in patients with tongue squamous cell carcinoma compared with normal samples. Methylation profiling using salivary DNA is considered a non-invasive alternative to tissue samples. Hence, the present study tested the DNA methylation status of these four promoters as indicators of oral cancer progression. METHODS: We performed the bisulfite-based targeted next-generation sequencing of four candidate genes in saliva and tissue DNA from normal, premalignant, and squamous cell carcinoma subjects. The clinicopathological association, diagnostic, and prognostic utility of aberrant DNA methylation were evaluated using the TCGA-HNSCC dataset. Using the Xgboost algorithm and logistic regression, CpG sites were prioritized, and Receiver Operating Characteristic was generated. By Log-rank test and Kaplan-Meier (KM) curves, an association between methylation and overall survival (OS), disease-free interval (DFI), and progression-free interval (PFI) were computed. RESULTS: We identified all four genes as significantly hypermethylation in premalignant and malignant samples compared with normal samples. The methylation levels were comparable between saliva and tissue samples with an r-value of 0.6297 to 0.8023 and 0.7823 to 0.9419 between premalignant tissue vs. saliva and OC vs. saliva, respectively. We identified an inverse correlation between DAPK1, LRPPRC, RAB6C, and ZNF471 promoter methylation with its expression. A classifier of 8 differentially methylated CpG sites belonging to DAPK1, RAB6C, and ZNF471 promoters was constructed, showing an AUC of 0.984 to differentiate tumors from normal samples. The differential methylation status of DAPK1, LRPPRC, and ZNF71 promoters was prognostically important. Abnormal expression of all four genes was associated with immune infiltration. CONCLUSIONS: Thus, methylation analysis of these candidate CpG sites from saliva can be helpful as a non-invasive tool for the clinical management of OC.

show abstract

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer

Fohlin¹,

Bekkhus

Sandström

et al. 2020

mol clin onc

View full text Add to dashboard Cite

Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemically untreated patients with estrogen receptor (ER)-positive/progesterone receptor (PR)-negative tumors with high Ras-related protein Rab-6C (RAB6C) expression levels (RAB6C +) had prolonged distant recurrence-free survival compared with that of patients exhibiting low RAB6C (RAB6C-)-expressing tumors. The aim of the present study was to investigate whether RAB6C predicts the effectiveness of tamoxifen treatment. The present study used a dataset comprising 486 female patients with ER + tumors from a randomized study conducted by the Stockholm Breast Cancer Study Group between November 1976 and August 1990. The patients were considered as low-risk if their tumor size was ≤30 mm and their lymph node status was negative. Patients were followed up until distant recurrence, mortality or when 25 years after randomization was achieved, whichever occurred first. For patients with ER + /PR-/RAB6C + tumors, prolonged distant recurrence-free survival could not be observed if the patients were treated with tamoxifen [hazard ratio (HR), 1.82; 95% confidence interval (CI), 0.69-4.79; P= 0.23], whereas patients with ER + /PR-/RAB6Ctumors had 75% reduced distant recurrence risk (HR, 0.25; 95% CI, 0.09-0.70; P=0.008). In the ER + /PR + subgroup, patients with RAB6Cand RAB6C + tumors benefited from tamoxifen treatment, though it was most evident in the RAB6C + group (HR, 0.27; 95% CI, 0.13-0.58; P= 0.001). The results of the present study indicated that, for patients with ER + /PRtumors, those with low RAB6C expression benefited from tamoxifen treatment, whereas no benefit was observed in patients with high RAB6C levels.

show abstract

Expression of WTH3 in breast cancer tissue and the effects on the biological behavior of breast cancer cells

Cited by 4 publications

References 27 publications

Long-term prognostic and predictive factors in hormone receptor positive breast cancer

Long-term prognostic and predictive factors in hormone receptor positive breast cancer

Salivary DNA methylation markers for cancer of oral cavity

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer

Contact Info

Product

Resources

About